Last $13.30 USD
Change Today +0.79 / 6.31%
Volume 934.5K
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 4:00 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Snapshot

Open
$12.67
Previous Close
$12.51
Day High
$13.42
Day Low
$12.67
52 Week High
07/30/14 - $15.95
52 Week Low
11/13/13 - $8.95
Market Cap
1.9B
Average Volume 10 Days
1.3M
EPS TTM
$-1.76
Shares Outstanding
120.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (IRWD)

ironwood pharmaceuticals inc (IRWD) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (IRWD) Details

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company’s lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

534 Employees
Last Reported Date: 02/7/14
Founded in 1998

ironwood pharmaceuticals inc (IRWD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $360.9K
Chief Scientific Officer, President of Resear...
Total Annual Compensation: $376.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $366.6K
Compensation as of Fiscal Year 2013.

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals, Inc. Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. announced the presentation of initial data from a Phase IIa clinical study in functional dyspepsia with IW-9179, an investigational guanylate cyclase-C (GC-C) agonist designed to target the upper gastrointestinal (GI) tract. These data will be presented during the American College of Gastroenterology 2014 Annual Scientific Meeting in Philadelphia, October 17 through October 22, 2014. Ironwood expects to initiate a Phase IIa clinical study evaluating IW-9179 in a second therapeutic area, gastro paresis, before the end of the year. Gastro paresis is an upper GI disorder that impacts an estimated 9 million Americans and is characterized by nausea, vomiting, bloating, early satiety and pain. The Phase IIa clinical study of IW-9179 was a randomized, double-blind study in 10 patients (six on IW-9179, four on placebo) with functional dyspepsia (FD). Patients treated with IW-9179 reported a numerically greater improvement from baseline, compared with placebo-treated patients, on six out of seven FD symptoms evaluated, including epigastric pain, epigastric bloating, postprandial fullness, early satiation, nausea and belching. The most common adverse event in IW-9179-treated patients was diarrhea. Enrollment in this study was limited by stringent enrollment criteria that sought to identify patients suffering only from GI symptoms of FD - a difficult task given that FD sufferers frequently also have symptoms of other GI disorders such as gastro esophageal reflux disease (GERD) or irritable bowel syndrome (IBS). In fact, of the 58 patients who initially met the stringent enrollment criteria and completed the 14-day pretreatment period, 78% were not qualified to enter the study treatment period owing to overlapping GI symptoms. These data inform Ironwood's continued work with gastrointestinal experts and regulatory authorities to define the path to bring forward new therapies in FD. These data will be presented in the poster, Evaluation of Daily GI Symptoms in a Phase 2a Study of IW-9179 in Functional Dyspepsia (abstract #P1637) on October 21, 2014, 10:30 a.m. to 4:00 p.m., Eastern Time. Jan Tack, MD, Ph.D., Head of Clinic in the Department of Gastroenterology, and Professor of Internal Medicine at the University of Leuven, Belgium, is the lead investigator and first author.

Ironwood Pharmaceuticals, Inc. Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation

Ironwood Pharmaceuticals, Inc. announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation (OIC). Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc, Ironwood's co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements (SBMs) per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.

Ironwood Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:00 AM

Ironwood Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Peter M. Hecht, Co-Founder, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $13.30 USD +0.79

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $4.65 USD -0.08
Nektar Therapeutics $13.25 USD +0.58
Progenics Pharmaceuticals Inc $4.61 USD +0.05
Sucampo Pharmaceuticals Inc $8.42 USD +0.41
Theravance Inc $17.17 USD +0.19
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.1x
Price/Book 12.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.